Neos Therapeutics Inc (NEOS.OQ)
17 Jan 2018
Wed, Nov 8 2017
* Neos Therapeutics reports third quarter 2017 financial results
* PDL Biopharma's proposal to acquire Neos Therapeutics expires today; PDL urges Neos to provide update on sale process
* Neos Therapeutics-co received paragraph iv certification from teva pharmaceuticals usa that teva submitted anda for generic version of cotempla xr-odt
U.S. drugmaker Neos Therapeutics Inc , which this week rejected a fourth takeover offer by PDL Biopharma Inc , will consider offers from other potential buyers, according to people familiar with the matter.
Oct 31 U.S. drugmaker Neos Therapeutics Inc , which this week rejected a fourth takeover offer by PDL Biopharma Inc, will consider offers from other potential buyers, according to people familiar with the matter.
* Says confirmed it received unsolicited proposal from PDL Biopharma to buy co for $10.25 per share in cash
* PDL Biopharma proposes to acquire NEOS THERAPEUTICS for $10.25 per share in cash
* Neos Therapeutics announces settlement with Actavis on Adzenys XR-ODT patent litigation
* Neos Therapeutics receives U.S. FDA approval of Adzenys ER™ (amphetamine) extended-release oral suspension for the treatment of ADHD in patients 6 years and older
BRIEF-Neos Therapeutics announces launch of Cotempla XR-OD extended-release orally disintegrating tablets for treatment of ADHD
* Neos Therapeutics announces launch of Cotempla XR-ODT™ (methylphenidate) extended-release orally disintegrating tablets for the treatment of ADHD in patients 6 to 17 years old Source text for Eikon: Further company coverage:
- Update: Neos Therapeutics Seems To Be Capitalizing On Pfizer's Decisions
- Your Daily Pharma Scoop: Aradigm Sees Sell-Off Ahead Of Ad Com, Editas Provides Update, Axsome Suffers Setback
- Neos Therapeutics: Buyout Target?
- Biotech Forum Daily Digest: Revisiting Neos Therapeutics
- Neos Therapeutics: Third-Quarter Results Point To Upside
- NEOS Is Poised To Take Advantage Of Missteps By Pfizer And Noven